MedTrace Logo

Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

NCT02007655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6372

Last updated 2022-06-07

No results posted yet for this study

Summary

The primary objectives of this study are:

* To estimate the incidence rate of unexpected adverse events
* To characterize the bleeding events and assess risk factors of bleeding
* To identify ancillary baseline variables that may also be associated with adverse outcomes

Conditions

  • NonValvular Atrial Fibrillation

Interventions

DRUG

Eliquis

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-01
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02007655 on ClinicalTrials.gov